Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Affimed secures additional E5 million in series B funding
This addition increases the total for the round to E30 million in equity. The capital increase was subscribed by Novo Nordisk via Novo Nordisk Biotech Fund, Novo Nordisk’s
This addition increases the total for the round to E30 million in equity. The capital increase was subscribed by Novo Nordisk via Novo Nordisk Biotech Fund, Novo Nordisk’s
To date, Ocera has raised a total of $62 million. In conjunction with the financing, Linda Grais of InterWest Partners will take a seat on the Ocera board
This Phase II trial, a randomized, double-blind, placebo-controlled, multiple dose study, will evaluate the efficacy and safety of three months of weekly injections of PC-DAC:Exendin-4 in patients with
The jury ruled that United States Surgical, a Covidien subsidiary, does not infringe Applied Medical’s US patent related to trocar seal technology. Scott Flora, president of Surgical Devices,
Under the agreement, members of Aetna network-based plans will be able to receive covered in-patient and out-patient services, at in-network rates, from the Indian River Medical Center, which
Under the terms of the agreement Upperton will use rP-nano technology to generate nanoparticles from recombinant proteins expressed in Novozymes’s proprietary, yeast-based expression system. The agreement extends previous
Midas will assist ABP in the introduction, marketing and promotion of the Accu-Break Technologies to potential collaboration partners. Additionally, Midas may assist ABP in the preparation of regulatory
Warburg Glycomed has expressed keen interest in collaborating with NextGen in a recently signed letter of intent, and is confident that a mutually beneficial deal can be arranged.
The study was designed to determine the safety, tolerability and preliminary evidence of preventive analgesic efficacy of orally administered ralfinamide at a dose range of 320/480mg per day,
SPE board member Alan Chalmers will oversee the office, located at Aeschenvorstadt 71, which will interact with the Swiss Agency for Therapeutic Products on planned future regulatory submissions